Figures computed from official regulatory filings — .
Ownershipinsiders 0% · institutions 0%
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for EASTGATE BIOTECH CORP only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Eastgate Biotech Corp., a development stage company, develops novel formulations of natural compounds and pharmaceutical products. The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes. It is also developing natural products and dietary supplements, including E-drops Nano and PURALEN that are self-nanoemulsifying compositions containing natural essential oils for oral administration; Glucora, a soft gelatin capsule with Banaba extract in self-emulsifying formulation for oral administration; URBAN POWER, a soft gelatin capsule with Ursolic acid and Banaba extract in self-emulsifying formulation for oral administration; Vitamin D3 nanoemulsion, a nanoemulsion with cholecalciferol; and Cleanezze, a hand sanitizer containing oil. Eastgate Biotech Corp. has collaboration with Biotech Corp. to develop a vaccine against COVID-19. The company was formerly known as Eastgate Acquisitions Corporation and changed its name to Eastgate Biotech Corp. in December 2014. Eastgate Biotech Corp. was founded in 1999 and is based in Toronto, Canada.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
18 buys— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Lukian Briantrack record | Buy | $41.5K | conv 49 |
| SEC |
| SCHWARZ JOSEPHtrack record | Buy | $44.9K | conv 40Cluster | SEC |
| GLUSKIN ANNA Etrack record | BuyD (derivative) | $49.8K | Cluster | SEC |
| WEISSPAPIR MICHAELtrack record | Buy | $44.9K | conv 40Cluster | SEC |
| Hasanagic Mirjana Miratrack record | BuyD (derivative) | $28.9K | Cluster | SEC |
| WEISSPAPIR MICHAELtrack record | BuyD (derivative) | $44.9K | Cluster | SEC |
| Hasanagic Mirjana Miratrack record | Buy | $28.9 | conv 38ClusterUnusual size | SEC |
| GLUSKIN ANNA Etrack record | Buy | $49.8K | conv 46Cluster | SEC |
| SCHWARZ JOSEPHtrack record | BuyD (derivative) | $44.9K | Cluster | SEC |
| Lukian Briantrack record | BuyD (derivative) | $41.5K | Cluster | SEC |
| WEISSPAPIR MICHAELtrack record | Buy | $38.2 | conv 31 | SEC |
| SCHWARZ JOSEPHtrack record | Buy | $38.2K | conv 38 | SEC |
| GLUSKIN ANNA Etrack record | Buy | $120K | conv 49Cluster | SEC |
| Hasanagic Mirjana Miratrack record | BuyD (derivative) | $51.3K | Cluster | SEC |
| Lukian Briantrack record | Buy | $106.8K | conv 63Cluster | SEC |
| TGT INVESTMENT MANAGEMENT INC. | BuyD (derivative) | $80.1K | ClusterFirst in 12mo | SEC |
| Hasanagic Mirjana Miratrack record | Buy | $68.4K | conv 48Cluster | SEC |
| TGT INVESTMENT MANAGEMENT INC. | Buy | $106.8K | conv 41ClusterFirst in 12mo | SEC |
| WEISSPAPIR MICHAELtrack record | BuyD (derivative) | $9K | Cluster | SEC |
| Lukian Briantrack record | BuyD (derivative) | $80.1K | Cluster | SEC |
| WEISSPAPIR MICHAELtrack record | Buy | $47K | conv 47Cluster | SEC |
| GLUSKIN ANNA Etrack record | BuyD (derivative) | $90K | Cluster | SEC |
| SCHWARZ JOSEPHtrack record | Buy | $47K | conv 37Cluster | SEC |
| SCHWARZ JOSEPHtrack record | BuyD (derivative) | $9K | Cluster | SEC |
| Lukian Briantrack record | BuyD (derivative) | $135K | ClusterFirst in 12mo | SEC |